Dr. Beth Y. Karlan Named New Editor-in-Chief for Gynecologic Oncology
Dr. Karlan has also selected a new editorial board and deputy editors
New York, 16 January 2008 – Beth Y. Karlan, M.D. has been named the new Editor-in-Chief of the Journal of Gynecologic Oncology, effective January 1, 2008. Dr. Karlan replaces David M. Gershenson, M.D. who has stepped down following 17 years as Editor-in-Chief of Gynecologic Oncology, the official publication of the Society of Gynecologic Oncologists (SGO).
“Gynecologic Oncology is a wonderful resource to our members and the profession at large, and I am really excited to have been selected to help lead and create its future direction and content,” commented Dr. Karlan.
Dr. Karlan is the Director of the Women’s Cancer Research Institute at Cedars-Sinai Medical Center, Los Angeles, and is also a Professor of Obstetrics and Genecology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). A long-time member of the SGO, Dr. Karlan has held a number of leadership positions within the Society, including serving as a member of the Communications, Government Relations, Informatics, and Program committees (of which she was Program Chairman); and various task forces; culminating in her tenure as SGO President in 2005–2006.
To assist in the journal’s publication, Dr. Karlan has selected a new, scientifically diverse editorial board and four new deputy Editors: Robert E. Bristow, M.D. (Johns Hopkins Medical Institutions), Barbara A. Goff, M.D. (University of Washington), Stephen C. Rubin, M.D. (University of Pennsylvania) and Anil K. Sood, M.D. (M.D. Anderson Cancer Center) The newly appointed team will work to raise the impact of the Journal in the medical community while ensuring that the publications are innovative and clinically relevant, and meet the highest standards of scientific integrity.
As Editor-in-Chief, Dr. Karlan is committed to improving the services to authors and reviewers as well as readers of the publication. “On a very positive note, we will be partnering with the SGO to offer CME (Continuing Medical Education) credits to reviewers, and to the first author of research articles published in the Journal”, Dr. Karlan noted.
# # #
Notes to Editors:
The Journal of Gynecologic Oncology is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. The Editorial team welcomes the submission of articles relating to the etiology, diagnosis, treatment, and prevention of female cancers, as well as research from any of the disciplines related to this field of interest. Research areas include: cell and molecular biology, chemotherapy, clinical trails, epidemiology, genetics, immunology and vaccines, ‘omics’, pathology and cytology, quality of life, radiation therapy, surgery, and translational research. Submissions on all aspects of scholarship related to tumors of this region are also sought, with originality, quality, and clarify the chief criteria of acceptance.
About the Society of Gynecologic Oncologists
The Society of Gynecologic Oncologists (SGO) is a national medical specialty society for physicians trained in the comprehensive management of women’s cancers. The Society’s membership is primarily comprised of gynecologic oncologists-obstetrician/gynecologists 3-4 years of additional, intensive training in the specific study of gynecologic cancers. SGO members provide medical and surgical care to women with ovarian cancer, cervical cancer, endometrial cancer, vulvar cancer, and vaginal cancer. They are trained in chemotherapy and radiation therapy administration, supportive care, and surgery in order to provide comprehensive patient care. More information on gynecologic oncology and the SGO may be found at www.sgo.org.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 212 633 3882